CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 26 enrolled
Drug / intervention
124-Iodine-cG250 (124I-cG250)drug
Likely dose
Not stated in record
Key inclusion· 5
  • ✓Presence of a renal mass
  • ✓Scheduled for surgical resection of renal mass
  • ✓Expected survival of at least 3 months
  • ✓Karnofsky performance scale ≥70
Key exclusion· 6
  • ✕New York Heart Association Class III/IV cardiac disease
  • ✕History of autoimmune hepatitis
  • ✕Chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to the first cG250 dose
  • ✕Allergy to iodine

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00199888
NCT00199888Phase 1Completed
CompareCT.gov

Pilot Study of Iodine-124 Labeled Chimeric G250 (124I-cG250) in Presurgical Patients With Renal Masses

Ludwig Institute for Cancer Research·interventional·Posted Sep 20, 2005·Updated Oct 10, 2022

In Brief

A Phase 1 clinical trial evaluating 124-Iodine-cG250 (124I-cG250) for Cancer of Kidney and 6 related conditions. Completed, enrolled 26 participants across 1 site.

Detailed Summary

The purpose of this study is to see if an antibody (cG250) attached to a radioactive substance (Iodine-124) safely detects clear cell renal cancer in patients with kidney tumors scheduled for surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer of Kidney, Kidney Cancer, Renal Cancer, Neoplasms, Kidney, Renal Neoplasms, Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma
CountriesUnited States
CollaboratorsMemorial Sloan Kettering Cancer Center

Timeline

Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 20, 2005
Enrollment StartJun 1, 2005
Primary CompletionMar 1, 2006
Study CompletionMay 29, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 20.8 years ago

Interventions

124-Iodine-cG250 (124I-cG250)drug